



## Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

September 2, 2021

BALA CYNWYD, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in 1x1 investor meetings at the Morgan Stanley 19<sup>th</sup> Annual Global Healthcare Conference taking place virtually September 9-15, 2021. Details for the live presentation can be found below.

Presentation Format: Fireside chat: [https://morganstanley.webcasts.com/starthere.jsp?ei=1488875&tp\\_key=ea9778aaf1](https://morganstanley.webcasts.com/starthere.jsp?ei=1488875&tp_key=ea9778aaf1)  
Date: Thursday, September 9, 2021  
Time: 5:00 PM ET

### About Larimar Therapeutics

Larimar Therapeutics, Inc. (Nasdaq: LRMR) is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: <https://larimartx.com>.

#### Investor Contact:

Joyce Allaire  
LifeSci Advisors  
[jallaire@lifesciadvisors.com](mailto:jallaire@lifesciadvisors.com)  
(212) 915-2569

#### Company Contact:

Michael Celano  
Chief Financial Officer  
[mcelano@larimartx.com](mailto:mcelano@larimartx.com)  
(484) 414-2715



Source: Larimar Therapeutics